Skip to main content
Clinical Trials/CTRI/2018/01/011393
CTRI/2018/01/011393
Recruiting
Phase 4

Comparative evaluation of efficacy & safety of Lurasidone & Olanzapine in patients of Schizophrenia:A Randomized,Parallel,Open-label, Clinical study

Dr Bhagyashree Mohod0 sites60 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Schizophrenia
Sponsor
Dr Bhagyashree Mohod
Enrollment
60
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Bhagyashree Mohod

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient of schizophrenia who is consulting first time to psychiatrist for the complaints
  • 2\. PANSS (positive and negative syndrome scale) score more than or equal to 80
  • 3\. Patient willing to give written informed consent.

Exclusion Criteria

  • Exclusion criteria :\-
  • 1\)Pregnant, Nursing Women and children
  • 2\)Patients requiring other psychotropic medications, central nervous system active drugs
  • 3\)Patient with neurologic disorders (dementia, seizures, stroke), obesity , serious or not stabilized organic disorders (neoplasia, cardiovascular, pulmonary, uncontrolled type 1 or 2 diabetes)
  • 4\)Patients with any other psychiatric disorders
  • 5\)Abnormal renal/hepatic function

Outcomes

Primary Outcomes

Not specified

Similar Trials